Search
Diagnosis in hematological diseases: morphology and flow cytometry
This SWG is active in disseminating knowledge on advances in the diagnosis and follow-up by morphology and multiparameter flow-cytometry of malignant and non-malignant hematological diseases. These include morphology, digital morphology, and flow-cytometry (mass, imaging, and spectral flow cytometry included).
Read morePieter Sonneveld appointed Officer in the Order of Orange-Nassau
The EHA Board congratulates former EHA President Professor Pieter Sonneveld on his appointment as an Officer of the Order of Orange-Nassau by His Majesty King Willem-Alexander of the Netherlands.
Read moreBENIGN HEMATOLOGY in 2023 and beyond
The term "benign hematology" has traditionally been used to refer to non-malignant blood disorders. However, over the past few years, questions have been raised as to the appropriate nomenclature for this category of diseases.
Read moreBurnouts: when caregivers become patients
Author: Côme Bommier (Young EHA Ambassador)
Affiliations: Hôpital St-Louis (Paris, France) & Mayo Clinic (Rochester MN, USA)
A survey will be released in September to further map burnout
among hematology professionals in Europe.
EHA supports the proposal for a Regulation on the European Health Data Space (EHDS)
On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.
Read more‘i4MDS’ consortium wins prestigious EHA Innovation Grant
In a significant development, the International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—known as the ‘i4MDS’— has received an esteemed EHA Innovation Grant.
Read morePosition of EHA on the Harmonization of Training and Education in Europe
The challenge
Education and training are largely national competencies.
Current status of the Clinical Trials Regulation
HemAffairs Article #2 – June 2019
In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- »